SCHEMBL1853258

SCHEMBL1853258

C1=COCCNCCOCCOCCNCCO1

nearest known ligand 0.67

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
KDM4E B2RXH2 1/20 0.58
GAA P10253 1/20 0.58
CYP2C9 P11712 1/20 0.58
HTT P42858 1/20 0.35
APEX1 P27695 1/20 0.34
TTR P02766 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30146940 0.88 MEN1 (0.44) MEN1KMT2AKDM4EGAACYP2C9
SCHEMBL11554769 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9
Morpholine SCHEMBL8649532 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9
SCHEMBL27350 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9
SCHEMBL11584070 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9
SCHEMBL25148109 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9
SCHEMBL11559655 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9
SCHEMBL7747664 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9
SCHEMBL111814 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9
SCHEMBL59830 0.82 MEN1 (1.00) MEN1KMT2AKDM4EGAACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5288718-A Desorption the formed complexes by administering tetraoxa-diazacyclooctadecane dimalonic acid tetrasodium salt ORSZAGOS "FREDERIC JOLIOT-CURIE" SUGARBIOLOGIAI ES SUGAREGESZSEGUGYI KUTATO INTEZET (HU) 1994-02-22 US claimed
US-20250090700-A1 HUMANIZED ANTIBODY THAT BINDS TO HEG1 PROTEIN AND COMPLEX OF ANTIBODY AND RADIONUCLIDE KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION (JP) 2025-03-20 US disclosed
EP-1838617-B1 CALCIUM POTASSIUM FERROCYANIDE, A PROPHYLACTIC MIXTURE COMPRISING THIS COMPOUND AND THE USE THEREOF FOR DECORPORATION OF RADIOCESIUM IN SUBJECTS AFFECTED BY NUCLEAR RADIATION SECRETARY DEPT ATOMIC ENERGY (IN) 2013-07-31 EP disclosed
US-7935366-B2 mixture with Calcium Iodate, and Calcium Carbonate for removal of all three radionuclides Cesium, Strontium, Iodine SECRETARY, DEPARTMENT OF ATOMIC ENERGY (IN) 2011-05-03 US disclosed
US-20080145448-A1 Calcium Potassium Ferrocyanide, a Prophylactic Mixture Comprising this Compound and the Use Thereof for Decorporation of Radiocesium in Subjects Affected by Nuclear Radiation SECRETARY, DEPARTMENT OF ATOMIC ENERGY GOVERNMENT OF INDIA (IN) 2008-06-19 US disclosed
EP-0426824-A1 METHOD FOR THE PREPARATION OF ACTIVE INGREDIENTS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATING RADIOACTIVE ISOTOPES FROM LIVING ORGANISMS ORSZAGOS "FREDERIC JOLIOT-CURIE" SUGARBIOLOGIA ES SUGAREGESZSEGUGYI KUTATO INTEZET (HU) 1991-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250090700-A1 HUMANIZED ANTIBODY THAT BINDS TO HEG1 PROTEIN AND COMPLEX OF ANTIBODY AND RADIONUCLIDE HIRIP3, PPHLN1, FRG1 MEN1 16/4885KMT2A 1777/4885KDM4E 3312/4885
US-20080145448-A1 Calcium Potassium Ferrocyanide, a Prophylactic Mixture Comprising this Compound and the Use Thereof for Decorporation of Radiocesium in Subjects Affected by Nuclear Radiation NEK6, NEK9, CASK MEN1 453/4885KMT2A 3551/4885KDM4E 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.